Ritu Lal

Dr. Ritu Lal is a leader in Pharmaceutical R and D. She has over 15 years of experience in Biotech/Pharma companies. Her passion is to bring healthcare products to patients in a cost-effective and efficient manner. In her role as a Senior Executive she has led Preclinical and Clinical Development teams in Biotech/Pharma companies. She has taken compounds from Discovery to Regulatory Approval and have filed more than 15 Investigational New Drug Applications (IND) in disease areas of neurology, inflammation, virology, pain and oncology. Two compounds have received New Drug Application (NDA) approvals from the US FDA and Ministry of Health and Welfare, Japan (Kaletra® for the treatment of HIV and Horizant® (Regnite® in Japan) for Restless Legs Syndrome (RLS) and Post Herpetic Neuralgia (PHN)).


Dr. Lal has a doctorate in Pharmaceutical Sciences and Pharmacology from the University of Maryland and a Masters degree in Pharmacology from University of Arizona. Dr. Lal has over 60 publications, book chapters and presentations.
She recently completed a Master’s in Management from Stanford University’s prestigious Sloan (MSx) Program at the Graduate School of Business. She has gained entrepreneurial and strategic frameworks to augment her health care industry experience.